Table 1 Patient characteristics
Disease-modifying therapy for MS | ||||||
|---|---|---|---|---|---|---|
GA | SC IFN-β-1b | SC IFN-β-1a | IM IFN-β-1a | Total group | P-value* | |
No. of patients | 44 (19%) | 60 (26%) | 66 (29%) | 59 (26%) | 229 (100%) | |
Age in years at time of enrolment | 48 (40–54) | 51 (44–58) | 45 (40–52) | 49 (41–55) | 48 (41–54) | 0.025 |
No. of female patients | 37 (84%) | 40 (67%) | 46 (70%) | 45 (76%) | 168 (73%) | 0.197 |
Body mass index in kg/m2 | 25 (22–27) | 25 (23–27) | 25 (23–27) | 25 (22–27) | 25 (23–27) | 0.871 |
Duration of MS in years | 8 (4–17) | 11 (4–17) | 7 (3–13) | 10 (4–14) | 9 (4–16) | 0.192 |
Duration of DMT in years | 5 (3–8) | 5 (3–12) | 4 (3–8) | 5 (4–10) | 5 (3–9) | 0.177 |
Use of auto-injector for injections of DMT | 33 (75%) | 52 (87%) | 49 (74%) | 18 (31%) | 152 (66%) | < 0.001 |